ForumIAS LATEST
- 15 Sept. | Current Affairs Pre-cum-Mains 2027 Morning 11 AM batch starts from 15th Sept. Click Here to Read More →
- 14 Sept. | Forum Residential Coaching (FRC) for UPSC preparation Click Here to know more →
- 14 Sept. | GS Advance Program (GSAP) for UPSC 2027 Mains starts from 14th Sept. Click Here to Read More →
- A large-scale trial of the world’s most advanced experimental malaria vaccine, Mosquirix, to give partial protection to children has begun in Malawi, Africa. In the upcoming week, the vaccine would be rolled out in Kenya and Ghana.
- Mosquirix has been developed by British pharmaceutical company GlaxoSmithKline in partnership with the PATH Malaria Vaccine Initiative. It was approved for the pilot programme in 2015.
- The field trial aims to immunise 1, 20,000 children aged 2 years and under to assess the effectiveness of the pilot vaccine and whether the delivery process is feasible.
- Malaria is disease caused by Plasmodium parasites that are transmitted to people through the bites of infected female Anopheles mosquitoes. According to WHO’s World Malaria Report 2018, more than 200 million people were affected by malaria in 2017. Africa has the highest malaria burden.
